NVAX
- Novavax, Inc.
()
Overview
Company Summary
Novavax, Inc. is a biotechnology company that specializes in developing vaccines for a range of infectious diseases. The company is primarily focused on utilizing its proprietary recombinant protein nanoparticle vaccine technology platform to create innovative vaccine candidates.
Novavax's vaccine development process begins with identifying specific viral antigens (proteins that trigger an immune response) that are responsible for causing the targeted disease. These antigens are then manufactured using recombinant DNA technology and self-assembled into nanoparticles. These nanoparticles, in turn, mimic the structure and characteristics of the virus, triggering a strong immune response in the body upon administration.
The company's approach offers several advantages. By solely focusing on the viral antigens instead of using the whole virus, Novavax can reduce the risk of vaccine-related side effects. Additionally, their technology allows for the production of vaccines without using live or attenuated viruses, further enhancing safety.
Novavax's pipeline includes vaccine candidates for different infectious diseases. Notably, the company gained significant attention for its COVID-19 vaccine candidate, NVX-CoV2373. This vaccine is designed to target the spike protein of the SARS-CoV-2 virus, which causes COVID-19.
The company conducts pre-clinical and clinical trials to evaluate the safety and efficacy of their vaccine candidates. If successful, Novavax seeks regulatory approvals, manufacturing partnerships, and distribution agreements to bring their vaccines to the market.
Novavax's ultimate goal is to contribute to public health by providing safe and effective vaccines to prevent the spread of infectious diseases and protect individuals and communities worldwide.